Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BSD Medical (Long Term Investment Oriented) -- Ignore unavailable to you. Want to Upgrade?

To: geoffrey Wren who wrote (113)	2/14/2013 11:49:37 AM
From: pleonastic	1 Recommendation Read Replies (1) \| Respond to of 178

Geoffrey: >The point about tumors consisting of differentiated cells is valid, but that sort of reasoning gets into the equation earlier: whether to explore heat-ablation as a type of treatment. At this point, the needed information is effectiveness in actual trials.< Sorry, but the above shows you are FAR behind in understanding the status of heat-ablation and, more generally, electrohyperthermia. Over several decades, MANY successful trials and a substantial level of clinical use have established beyond reasonable doubt that precision heating is a powerful cancer therapy. >For metastasized cancer, the important information is longevity after treatment for patients in similar classes, as well as some sort of qualify of life comparison, as even if one treatment provides no longevity superiority, it can be better re: side effects. I suppose some of that information is trickling in now.< “Trickle” is not the right word. Many Phase 1 trials (establishing safety) and Phase 2 trials (establishing significant or better efficacy) have been done over those years. The emphasis for some time now has been for Phase 3 trials (to establish efficacy levels relative to existing therapies). Several or more Phase 3 trials are further proving the efficacy of microwave electrohyperthermia and ablation – OVER established therapies. Various trials are summarized at http://investor.bsdmedical.com/press_releases/clinical_trials_and_research >For initial treatment, the important information is effectiveness at the apparent complete elimination of tumor in initial treatment, 5 year and 10 survival rates.< Long term results are a normal goal for Phase 3 trials, which also normally feature many patients, matched cohorts (one getting the new therapy, the other getting an older therapy), and (when feasible) “blind” dosing (patients, doctors do not know who gets what therapy). >There is a lot of information yet to be gathered. There is reason to be hopeful, but cancer like HIV and malaria has a long history of being resistant to treatment.< That is true. But, the fact is that the results – so far and including a fair number of Phase 3 trials – are very good for microwave hyperthermia. (Microwaves simply have the best wavelengths for indirect, precision heating – they work much better than the longer radiofrequency waves that reached medical practice earlier than microwaves). FURTHER – and in stark contrast -- microwave therapy has NO serious side effects. But, surgery, radiotherapy, and chemotherapy ALL have serious, inherent side effects. If all this is not enough, microwave electrohyperthermia also provides an effective method for delivering heat-release chemotherapy drugs directly to tumors (which are also made far more permeable to the drugs by being heated). The “bottom line”, as it clearly appears from solid theory, many successful trials, and actual practice (BSD Medical has developed three FDA-approved products): Microwave electrohyperthermia and ablation are breakthrough cancer therapies. Further, microwave electrohyperthermia is a powerful adjuvant for surgery, radiotherapy, and chemotherapy. Further, only the 2000-series products are still waiting approval – in the U.S., that is; they are already in practice in many other countries. IMO – and evident! -- microwave cancer therapy is LATE-TERM PREGNANT for widespread expansion!